Stock Information
symbol line chart

SOPHSOPHiA Genetics SA

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Jurgi Camblong

Location

N/A, Switzerland

Exchange

Nasdaq

Website

https://sophiagenetics.com

Summary

SOPHiA GENETICS SA operates as a healthcare technology company.

Company Info

CEO

Jurgi Camblong

Location

N/A, Switzerland

Exchange

Nasdaq

Website

https://sophiagenetics.com

Summary

SOPHiA GENETICS SA operates as a healthcare technology company.

AI Insights for SOPH
5 min read

Quick Summary

SOPHiA Genetics SA is a Switzerland-based healthcare technology company focused on data-driven medicine. The company operates a cloud-based software-as-a-service platform that helps healthcare providers analyze complex multimodal data. Its platform is used to generate clinical and biological insights from genomic, radiomic, and other diagnostic data sources. SOPHiA Genetics primarily sells software, analytics, and related data services rather than traditional pharmaceutical products. Its main customers include hospitals, clinical laboratories, cancer centers, academic medical institutions, and biopharma organizations that need scalable tools for precision medicine and diagnostic interpretation.

Strengths

•

SOPHiA Genetics has a differentiated position as a healthcare technology company focused on cloud-based data analytics for precision medicine.

•

Its platform addresses a large and growing need for hospitals, laboratories, and biopharma companies to interpret complex genomic and multimodal data.

•

The company has meaningful revenue, with operating revenue of about 77.3 million and gross profit of about 52.1 million in the supplied period.

•

Its gross profit base suggests the software-oriented business model has potential scalability if revenue growth continues and operating expenses are controlled.

•

The company is also positioned in an attractive market segment because AI, personalized medicine, diagnostics, and data-driven healthcare are all long-term growth themes.

Key Risks

•

A key risk is that SOPHiA Genetics may continue to burn cash if revenue growth is not enough to cover operating expenses.

•

The company’s negative earnings and operating losses create financing risk, especially if capital markets become less favorable for unprofitable growth companies.

•

Competitive pressure from Tempus AI, Illumina, Qiagen, and other healthcare AI or genomics companies could limit pricing power and customer adoption.

•

Healthcare data businesses also face regulatory, privacy, data quality, integration, and clinical validation challenges.

What to Watch

The most recent reported data show total revenue of about 77.3 million and gross profit of about 52.1 million, indicating that the company continues to generate meaningful platform revenue but has not reached profitability.
Operating losses remained substantial, with total operating income around negative 70.9 million.
Recent coverage highlighted SOPHiA Genetics as an unprofitable company that is growing revenue faster than its industry and maintaining an adequate cash runway.
The company was also mentioned in broader AI biotechnology market research alongside companies such as NVIDIA, Tempus AI, Recursion, Schrodinger, Illumina, Qiagen, and Insilico Medicine.
No specific quarterly product launch, acquisition, or named partnership was provided in the data, so the main quarter narrative appears to be continued growth in a difficult profitability environment.

Price Drivers

•

SOPH’s stock price is likely driven by revenue growth, cash runway, progress toward profitability, and investor appetite for healthcare AI companies.

•

The company remains unprofitable, with negative basic EPS of -1.11, diluted EPS of -1.17, net income of about -79.0 million, and operating income of about -70.9 million.

•

Because earnings are negative, investors are likely focusing more on revenue growth, gross profit, platform adoption, and operating expense discipline than on traditional earnings multiples.

•

The valuation is also sensitive to growth expectations because EV to revenue is about 6.74 and price to book is about 11.20, which can be demanding for an unprofitable company.

•

Broader market enthusiasm for AI in biotechnology, diagnostics, and personalized medicine can support the stock, while healthcare technology selloffs or macro risk aversion can pressure it.

Recent News

•

Recent news mentioned SOPHiA Genetics in a broader report on the global AI in biotechnology market.

•

The report identified the company as one of the featured companies in a sector expected to grow at a 20% compound annual growth rate through 2030.

•

Another recent article highlighted SOPHiA Genetics as a penny-stock-style opportunity, noting that it is unprofitable but growing revenue faster than the industry.

•

That article also pointed to strategic healthcare software partnerships and an adequate cash runway as positives.

•

There were no specific recent acquisitions, controversies, or named new partnerships included in the supplied news items.

Market Trends

•

The broader market trend supporting SOPHiA Genetics is the increasing use of artificial intelligence in biotechnology, diagnostics, and personalized medicine.

•

The supplied news states that the global AI in biotechnology market was valued at $3.8 billion in 2024 and is projected to reach $11.4 billion by 2030.

•

Growth drivers include faster drug discovery, early disease detection, personalized medicine, AI investment, aging populations, and the rising prevalence of chronic disease.

•

At the same time, the sector faces challenges such as data quality, algorithmic bias, integration complexity, privacy concerns, ethics, and regulation.

•

SOPHiA Genetics is exposed to both sides of this trend because its business can benefit from rising demand for healthcare data analytics, but its execution must be strong in a market that is technically complex and highly competitive.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on SOPH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show